Merus

Merus is a clinical-stage immuno-oncology company that researches and develops bispecific antibody therapeutics for the treatment of cancer.

Business Model:

Revenue: $45.6M

Employees: 51-200

Detailed Merus Information

Geographic Data

Merus headquarters map

Address: Yalelaan 62

City: Utrecht

State: utrecht

Zip: 3584 CM

Country: NL

Financial Info

Stage:

post ipo equity

Raised Last:

$56M

Raised Total:

$289M

Metrics

2,231,449Website Global Rank

6,975Website Monthly Traffic

Twitter Followers

Description

Merus is a clinical-stage immuno-oncology company that researches and develops bispecific antibody therapeutics for the treatment of cancer.

Contact Phone:

Contact Email:

Merus went public on 5/20/2016 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
5/20/2016

Ticker Symbol:
MRUS

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2018 Post-IPO Equity 3 $55.8M Sofinnova Investments
EQT life science
Biotechnology Value Fund
Sofinnova Investments
EQT life science
Biotechnology Value Fund
10/2013 Series B 5 $42.2M Johnson &a; Johnson Development Corporation
Pfizer Venture Investments
Novartis Venture Fund
EQT life science
Bay City Capital
Johnson &a; Johnson Development Corporation
4/2015 Series C 10 $79.1M RA Capital Management
Bay City Capital
Novo Holdings
Tekla Capital Management
Johnson &a; Johnson Innovation
EQT life science
Rock Springs Capital
Novo Holdings
Sofinnova Investments
Pfizer Venture Investments
Novartis Venture Fund
RA Capital Management
Bay City Capital
Novo Holdings
Tekla Capital Management
Johnson &a; Johnson Innovation
EQT life science
Rock Springs Capital
Novo Holdings
Sofinnova Investments
8/2015 Series C $80.5M Sofinnova Ventures
Novo A/S
RA Capital Healthcare Fund
Rock Springs Capital
Tekla Capital Management
Novartis Venture Fund
Bay City Capital
Life Sciences Partners
Aglaia Biomedical Ventures
1/2006 Series A -
11/2016 Grant $1.6M
1/2021 Post-IPO Equity $120M
1/2017 Post-IPO Equity $80M
5/2016 IPO $60M
10/2013 Series B $42M Aglaia BioMedical Ventures B.V.
Bay City Capital
Novartis Venture Fund
Johnson & Johnson Development Corporation
Life Sciences Partners
1/2010 Series B $0 Bay City Capital
EQT life science
Novartis Venture Fund
Pfizer
Aglaia BioMedical Ventures
Bay City Capital
EQT life science
Novartis Venture Fund
Pfizer
Aglaia BioMedical Ventures
1/2010 Series B 5 $30.1M Bay City Capital
EQT life science
Novartis Venture Fund
Pfizer
Bay City Capital
EQT life science
Novartis Venture Fund
Pfizer
1/2006 Series A -
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research